CD274 and non-small cell lung carcinoma: The latest data from the CheckMate 227 study reaffirmed the significant survival benefit of “O+Y” for the first-line treatment of metastatic NSCLC. The 6-year OS rates of the combination therapy were superior to those of the chemotherapy group (9% increase in 6-year OS rates for patients with PD-L1 ≥1%; 11% increase in 6-year OS rates for patients with PD-L1 <1%). Median OS was prolonged by 4.8 months in the nivolumab combined with ipilimumab group.